Synergy Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 58   

Articles published

SGYP 3.90 +0.12 (3.17%)
price chart
Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2
Synergy Pharma is developing plecanatide for other indications as well. In Apr 2014, the company initiated a second phase III study on plecanatide in adults suffering from chronic idiopathic constipation (CIC).
Synergy Pharmaceuticals Reports Second Quarter and First Half 2014 Financial ...  Wall Street Journal
Related articles »  
Synergy Pharmaceuticals to Present at Canaccord Genuity Growth Conference
NEW YORK, Aug 06, 2014 (BUSINESS WIRE) -- Synergy Pharmaceuticals Inc. SGYP, +4.53% today announced its Chairman and Chief Executive Officer, Dr.
Traders Recap - Synergy Pharmaceuticals Inc (NASDAQ:SGYP), M.D.C. ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) opened the session at $3.65, trading in a range of $3.52 to $3.73, and closed at $3.61.
Hot News: Synergy Pharmaceuticals (NASDAQ:SGYP), Intra-Cellular Therapies ...  Crazy Joys
Related articles »  
Investor's Alert - Synergy Pharmaceuticals Inc (SGYP), Texas Roadhouse Inc ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) opened the session at $3.81, trading in a range of $3.77 - $3.90, and closed at $3.79.
Related articles »  
Aegis Trims Synergy Pharmaceuticals Target Price to $20.00 (SGYP)
Synergy Pharmaceuticals Inc logo Synergy Pharmaceuticals (NASDAQ:SGYP) had its price target decreased by Aegis from $26.00 to $20.00 in a research report sent to investors on Thursday morning.
Hot Stocks: Cummins Inc. (NYSE:CMI), CytRx Corporation (NASDAQ:CYTR ...
The share price of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) decreased 5.5% after the company announced its second-quarter results on Aug 11.
Synergy Pharmaceuticals Stock Price Down 6.3% on Disappointing Earnings ...
Synergy Pharmaceuticals logo Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) fell 6.3% on Tuesday following a dissappointing earnings announcement, Analyst Ratings Net reports.
Trend Analysis Report - LeapFrog Enterprises, Inc. (LF), Synergy ...
Synergy Pharmaceuticals Inc (NASDAQ:SGYP), recently revealed its financial results and business update for the three and six months ended June 30, 2014.
Related articles »  
Trouble For Synergy Pharmaceuticals Shorts With Pending SP-333 Trial Results
I wrote an article about Synergy Pharmaceuticals (NASDAQ:SGYP) ("Synergy" or "the company") in November of last year right before the stock made a significant move leading up to Phase 2 IBS-C results.
Active Stocks : Carriage Services Inc. (NYSE:CSV), Semtech (NASDAQ:SMTC ...
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) announced Monday that it has reached the halfway mark for total enrollment in the first pivotal phase 3 trial of plecanatide in patients with chronic idiopathic constipation or CIC.
Related articles »